Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing will propel the progress of Rapafusyn's innovative and diverse pipeline of macrocyclic peptide-based non-degrading molecular glues for the treatment of neoplasms.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Peptide
Partner/Sponsor/Collaborator: 3E Bioventures Capital
Deal Size: $28.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 20, 2024